Literature DB >> 15094085

Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes.

Anders A F Sima1, Hideki Kamiya, Hideke Kamiya, Zhen Guo Li.   

Abstract

Diabetes is an increasingly common disorder which causes and contributes to a variety of central nervous system (CNS) complications which are often associated with cognitive deficits. There appear to be two types of diabetic encephalopathy. Primary diabetic encephalopathy is caused by hyperglycemia and impaired insulin action, which evolves in a diabetes duration-related fashion and is associated with apoptotic neuronal loss and cognitive decline. This appears to be particularly associated with insulin-deficient diabetes. Secondary diabetic encephalopathy appears to arise from hypoxic-ischemic insults due to underlying microvascular disease or as a consequence of hypoglycemia. This type of cerebral diabetic complication is more common in the type 2 diabetic population. Here, we will review the clinical and experimental data supporting this conceptual division of diabetic CNS complications and discuss the underlying metabolic, molecular, and functional aberrations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15094085     DOI: 10.1016/j.ejphar.2004.02.056

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  45 in total

1.  Neuroprotective effect of N-acetylcysteine in the development of diabetic encephalopathy in streptozotocin-induced diabetes.

Authors:  Sukhdev Singh Kamboj; Kanwaljit Chopra; Rajat Sandhir
Journal:  Metab Brain Dis       Date:  2008-09-19       Impact factor: 3.584

Review 2.  Glycemic extremes in youth with T1DM: the structural and functional integrity of the developing brain.

Authors:  Ana Maria Arbelaez; Katherine Semenkovich; Tamara Hershey
Journal:  Pediatr Diabetes       Date:  2013-10-14       Impact factor: 4.866

3.  Reduced gap junctional communication among astrocytes in experimental diabetes: contributions of altered connexin protein levels and oxidative-nitrosative modifications.

Authors:  Kelly K Ball; Lamia Harik; Gautam K Gandhi; Nancy F Cruz; Gerald A Dienel
Journal:  J Neurosci Res       Date:  2011-05-02       Impact factor: 4.164

4.  Gallic acid modulates cerebral oxidative stress conditions and activities of enzyme-dependent signaling systems in streptozotocin-treated rats.

Authors:  I J Kade; J B T Rocha
Journal:  Neurochem Res       Date:  2013-02-05       Impact factor: 3.996

5.  Brain effect of insulin and clonazepam in diabetic rats under depressive-like behavior.

Authors:  Carlos Alberto Yasin Wayhs; Caroline Paula Mescka; Camila Simioni Vanzin; Graziela Schmitt Ribas; Gilian Guerreiro; Maurício Schüler Nin; Vanusa Manfredini; Helena Maria Tannhauser Barros; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2013-03-27       Impact factor: 3.584

6.  Effect of sesamol on diabetes-associated cognitive decline in rats.

Authors:  Anurag Kuhad; Kanwaljit Chopra
Journal:  Exp Brain Res       Date:  2007-10-23       Impact factor: 1.972

7.  Combined effects of hyperglycemic conditions and HIV-1 Nef: a potential model for induced HIV neuropathogenesis.

Authors:  Edward A Acheampong; Cassandra Roschel; Muhammad Mukhtar; Alagarsamy Srinivasan; Mohammad Rafi; Roger J Pomerantz; Zahida Parveen
Journal:  Virol J       Date:  2009-10-30       Impact factor: 4.099

8.  Hyperglycaemia and diabetes impair gap junctional communication among astrocytes.

Authors:  Gautam K Gandhi; Kelly K Ball; Nancy F Cruz; Gerald A Dienel
Journal:  ASN Neuro       Date:  2010-03-15       Impact factor: 4.146

9.  Diabetes and Alzheimer's disease - is there a connection?

Authors:  Anders A F Sima; Zhen-Guo Li
Journal:  Rev Diabet Stud       Date:  2007-02-10

10.  Presence of the APOE epsilon4 allele modifies the relationship between type 2 diabetes and cognitive performance: the Maine-Syracuse Study.

Authors:  G A Dore; M F Elias; M A Robbins; P K Elias; Z Nagy
Journal:  Diabetologia       Date:  2009-08-20       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.